นโยบายงานวิจัย /จรรยาบรรณนักวิจัย /ระดับคุณภาพบทความวิจัยตีพิมพ์ /ระดับคุณภาพผลงานวิชาการ /แหล่งทุน /ดาวน์โหลด /ฐานข้อมูลวิจัย /วิเคราะห์-สังเคราะห์งานวิจัย /ลิขสิทธิ์ /ข่าว


Evaluation of adverse drug reactions in solid tumor patients receiving oral targeted therapy at Sunpasitthiprasong hospital Ubon Ratchathani


Author

-

Manit Saeteaw, Thunyarak Poomuang, Thanakorn Tanchaweng,

Wannaporn Wattanawong and Saran Kitsaran


Journal

- The 11th Annual Conference of Northeast Pharmacy Research 2019

Volume

- 0

Year

- 2562

Publication type

-

Page list

- -

Abstract

   

Introduction: Treatment of cancer with oral targeted therapy has direct effect on cancer cell which may provide higher efficacy and safety than conventional chemotherapy treatment. However, adverse drug reactions (ADRs) from oral targeted therapy have been reported from numerous studies. These ADRs may affect to cancer treatment outcomes and patient’s quality of life. Objectives: The purpose of this study was to evaluate proportion and incidence of adverse drug reactions from oral targeted therapy. Methods: A cross-sectional study was conducted in solid tumor patients who had received the oral targeted therapy at Suppasitthiprasong Hospital during 1st January 2014 to 31st December, 2017. Reported ADRs were analyzed by descriptive statistics, McNemar test was used to compare ADRs incidences before and after oral targeted therapy. Statistical analysis was done using SPSS version 16.0. Result: In total, 103 cancer patients were enrolled in this study. Majority of patients were male) 54.4%) with the average age of 63.6 years old. Gastrointestinal stromal tumor (37.9%) was the most common cancer. ADRs were observed in all patients receiving oral targeted therapy. The most frequent detected ADR was anemia (95.8%), followed by neutropenia (76.5%) and thrombocytopenia (14.3%), respectively. Incidence of all hematologic toxicity after treatment significant increased from before treatment (P<0.05). Comparing ADRs within subgroup classification of pharmacological activity, neutropenia was more likely to be identified as an ADR from intracellular kinase group (imatinib and everolimus) (P<0.05). Conclusion: High proportion of ADRs had been notified in all patients. Significant Increment of ADRs incidence was observed after receiving oral targeted therapy. Hence, monitoring of ADRs from this drug group should be of concern.


Keywords

   

Oral targeted therapy, adverse drug reactions, cancer